Compare DexCom, Inc. (DXCM) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Workday Inc — how do they compare? DexCom, Inc. trades at $83.67 (market cap $31.86B), while Workday Inc trades at $187.64 (market cap $45.26B). The key difference: Workday Inc is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Workday Inc for 38 Days on average.
| DXCM | WDAY | |
|---|---|---|
Market Cap | $31.86B | $45.26B |
Volume | 3,607,070 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $92.34 | $245.67 |
52-Week Low | $54.84 | $112.55 |
Typical Hold Time | 62 Days | 38 Days |
Enterprise Value | $31.32B | $45.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Workday (WDAY) trades at $184.26, down 1.23% on the day amid a broader tech selloff, with a bearish technical signal. The company shows strong revenue growth, reaching $8.45B in 2025, and has consistently beaten earnings estimates. Recent strategic moves include AI product launches and a 2.5% headcount reduction aimed at efficiency. Analyst consensus is bullish with a $202.92 price target, but negative net cash flow and high valuation ratios present risks.
The outlook for WDAY is mixed; strong fundamentals and AI integration offer growth potential, but high P/E of 38.25 and recent layoffs signal execution risks. Investors should weigh robust analyst support against valuation concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
